Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Down 51.5% in May

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the recipient of a significant decline in short interest in May. As of May 29th, there was short interest totaling 10,140 shares, a decline of 51.5% from the May 14th total of 20,907 shares. Based on an average daily trading volume, of 16,983 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 30th. Weiss Ratings downgraded Biodexa Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 2.6%

Shares of NASDAQ:BDRX traded up $0.08 on Monday, hitting $3.11. The stock had a trading volume of 14,110 shares, compared to its average volume of 438,450. Biodexa Pharmaceuticals has a twelve month low of $2.86 and a twelve month high of $66.50. The firm’s 50 day moving average price is $3.52 and its 200-day moving average price is $8.67.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its earnings results on Friday, March 27th. The company reported $3.52 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.53.

Institutional Investors Weigh In On Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals makes up approximately 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest holding. Sabby Management LLC owned about 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.